Review Article - Global Journal of Dentistry and Oral Hygiene ( 2023) Volume 10, Issue 1

Analysis of oral cancer specific biomarkers as a validation tool for future diagnosis

M Athar^* and S Malviya Department of Biochemistry, Sri Satya Sai University of Technology and Medical Sciences, Madhya Pradesh, India
^*Corresponding Author:
M Athar, Department of Biochemistry, Sri Satya Sai University of Technology and Medical Sciences, Madhya Pradesh, India, Email: athar.fsl48@gmail.com

Received: 21-Sep-2022, Manuscript No. GJDOH-22-76491; Editor assigned: 23-Sep-2022, Pre QC No. GJDOH-22-76491 (PQ); Reviewed: 07-Nov-2022, QC No. GJDOH-22-76491; Revised: 27-Dec-2022, Manuscript No. GJDOH-22-76491 (R); Published: 03-Jan-2023, DOI: 10.15651/2449-1918.23.10.017

Introduction

Carcinogenesis is a baffling cycle that occurs at the total and genotype levels. Disease headway is driven by the gathering of genetic what's more, epigenetic changes that resentful the homeostatic harmony between cell development and cell demise. The nuclear level changes that occur in carcinogenesis are:

• Disease cell extension without external upgrades.
• Harshness toward inhibitory advancement signals.
• Aversion of apoptosis of course cell death frameworks as well as commencement of ant apoptotic characteristics.
• Boundless explicative potential.
• Upheld angiogenesis.
• Interruption what's more.
• Metastasis limit.
• Genomic unsteadiness.
• Also proto-oncogene's change achieved by slips away in DNA fix.

Research on disease tissues has uncovered that there may be an association between sub-nuclear level and tissue level changes that drive perilous changes in the tissue and expect a huge part in sickness movement. The construing can be drawn is that an examination of the regular particles drew in with the sub-nuclear arrangement of carcinogenesis could give significant suggestive data, i.e., biomarkers, on the disease sickness process. The national cancer foundation has portrayed "biomarker" as a natural molecule found in blood, other body fluids, of tissues that means that a run of the mill or uncommon cycle, or of a condition of sickness, for instance, malignant growth. Biomarkers assume a significant part in distinctive the presence or nonappearance of disease (Azzam G et al., 2012).

Clinical Applications and Oral Cancer Biomarker Considerations

Biomarkers can be used to evaluate patients in a variety of clinical settings. They assess the risk of illness, screen for cancers of mysterious life, distinguish harmless detection from dangerous detection/one type of harm from another, make predictions, and act as indicators/screening. Can be used to check the infection status. Biomarkers can be used to distinguish replication and to determine movement/response to treatment. If the risk reduction method or screening is successful, the certainty that the patient may be at risk of developing oral cancer is useful. These steps are much more proficient when applied to high-risk kibbles than applying discounts to the entire population. Salivary biomarkers such as L-phenylalanine act as screening biomarkers and are useful for early detection and screening of Oral Squamous Cell Carcinoma (OSCC). Cloning of grade 2 acidic lactase is a proteomic biomarker used to d istinguish cancer cells from adenocarcinoma (Bandres E et al., 2006).

Literature Review

Genomic biomarkers such as integral α3 and integral β4 are strongly associated with distant metastasis and tumor prediction. 60 vascular endothelial development factors, B-cell lymphoma-2, claudin 4, ja related protein 1, MET protooncogene and receptor tyrosine kinases have been proposed as an ingenious collection of biomarkers that serve as useful screening and radio resistance indicators (Bansal SK et al., 2013).

Biomarker Reporting and Evaluation Conventions

The consistency of biomarker biopsy samples can be radically changed at the assortment, handling, and volume stages. This has created biomarker publication rules to reduce the difficulty of experimental and logical results and ensure that all important data are included. The standard rules for reporting biomarkers are Biosample Reporting for High Quality Concentration (BRISQ), Proposed Growth Marker Reporting (REMARK), Analytical Accuracy Reporting Criteria (STARD), and the minimum data (MIAME) for microarray search. BRISQ and REMARK continue to provide models for presenting the complexity of pre- analysis. Insightful questions related to the expected prognostic elemental concentrations in a coordinated and easy way. STARD and MIAME for the dissemination of analytical tests provide rules for the details of microarray research. Biomarker scoring rules have been developed to determine the clinical utility of the identified biomarkers. The American Society of Clinical Oncology's Tumor Marker Guidelines Committee has proposed the Growth Marker Utility Reviewing Framework (TMUGS) to work with the basic assessment of biomarkers (Baraniskin A et al., 2011).

Salivary Diagnostics Translational Applications

Saliva is a multi-component oral liquid suitable for both oral and underlying medical problems. Saliva testing has proven to be a useful symptomatic tool for other distant malignancies such as breast cancer and lung cell destruction Sjogren's disease and pancreatic cancer (Barnes L et al., 2005).

Spit can be used as an indicator of the disease. Includes markers. According to the National Institutes of Health (NIH), biomarkers are marks that are fairly evaluated and evaluated as signs of drug response to typical natural processes, pathogen interactions, or restorative mediation. Biomarkers must be validated and approved prior to clinical use and may be effective or applicable in health risk assessment. Responsiveness is a true positive rate expressed at the level of the total number of people with a disease that tests positive. Specificity is the true negative rate, which estimates the range of people who are pessimistically tested for infection but are not actually ill. The area under the Collector Working Quality Bend (AUC) is also an important estimate in indicating biomarker performance. The AUC of a biomarker verification test ranges from 50%, which indicates that you understand only the possibilities, to 100%, which indicates an ideal demonstration test (Bartel DP et al., 2004).

Challenges of Biomarkers in Cancer Studies

The ideal cancer biomarker is a well-defined marker of injury and should not be confused with threat tissue and non-malignant tissue, clarifying the nature of the injury and not coordinating with other threat types. It should also be noted that ideal cancer biomarkers should limit false positive tests and provide reliable and reliable wounds, and no abnormally elevated records or proteins have been found in cancer. Most of the new cancer biomarkers have sites with signaling pathways characteristic of typical cells and tissues, such as cell proliferation, cell isolation, apoptosis, angiogenesis, cell death, and exacerbation. Thus, biomarkers transmitted in the cell nucleus or cytoplasm are not disclosed and thus the exported cell surface or protein is considered. In addition, record proteins are generally transmitted at expanded levels and therefore have low expression and therefore flop as candidate biomarkers. Cancerous tissue is composed of altered cells that result from mutations. Based on the damage, the acquired genetic weakness of the growing cells can promote the development of a subpopulation of cancer cells (called clones) that may expand somewhat due to developmental potential. In addition, during cancer movement, new clones are more likely to emerge through genetic and epigenetic modifications. This peculiarity is called "Colonel Diversity". Colonel diversity is the result of a series of changes and fundamental changes that occur within a single histological type of cancer and result in an heterogeneous population of cells. Histological changes that usually occur with the maturation of clone diversity, heredity, or, on the other hand, further cancer detection techniques in connection with cancer research (Bhadage CJ et al., 2013).

OSCC and Salivary Biomarkers

Circlin DNA from tumours: During physiological cell turnover or especially neurological situations, apoptotic and necrotic cells release debris and DNA/RNA atoms into body fluids. Under physiological conditions, cell-specific particles and suspended matter are carried out by scavenger cells. All other conditions are the same, but in patients with malignant tumors, this system creates weaknesses that promote the accumulation of sans-cell DNA (cfDNA) in the tissue microenvironment and organic fluids. Therefore, sick patients have elevated levels of cfDNA in body fluids. Leakage of cfDNA from malignant proliferating cells, also known as ctDNA, can be distinguished from cfDNA physiologically released from non-disease cells by several highlights (fluid fixation, significant changes, overall size). As a result of irregular fractional assimilation of genomic DNA, cfDNA from apoptotic cells is estimated to match 180-200 bases. Corruption or autophagy during malignant growth most often produces larger DNA particles in the 100-400 base set. According to many studies, ctDNA in diseased patients has genetic and posterior changes seen in histology of harmful wounds, as well as many other malignancies such as size, cell turnover, stage, vascular distribution, drug response, etc. It is essential that it is also shown to reflect growth characteristics. ctDNA connection focus. Several systems, whether ever suspected or not, are recommended to understand the arrival of ctDNA in body fluids from sick patients (Bishop JA et al., 2010). The cause of the increased number of apoptotic/necrotic cells is very likely to be a sequela of accelerated digestion of diseased cells. Malignant proliferating cells that shed from the essential cancerous mass and spread throughout the body fluid (eg, CTC) can effectively deliver fragments of cellular nucleic acids that cause neoplastic changes when integrated from nondisease cells. Disease changes can also be a sequela of healthy cell assimilation of vesicles (e.g., EV) containing ctDNA that have been effectively deprived of malignant proliferating cells. ctDNA is mainly released into the circulatory system. In any case, it can also be detected in other body fluids. For example, by extrafiltration of salivary organs, individual dissemination, or dynamic media, ctDNA can easily migrate from adjacent sites and circulatory system to saliva and convey information about major proliferation or potential metastases. The study of ctDNA in saliva is much more delicate than the study of the circulatory system because it is less attenuated and less contaminated (Bourguignon LY et al., 2012).

Vesicles that are Extracellular

As is well known, EVs correspond to one of the basic means of intercellular correspondence. The discovery of cell oriented EVs in saliva, ready to specifically "bundle" factors such as DNA, RNA, miRNAs, and proteins, has recently been seen by experts as a promising additional source of biomarkers. To this point, the most studied disease enhancing and motor vesicles are ectospores and microvesicles, comparable to some major and beneficial components, but in small layers recognized by size and cell shedding process. It is a vesicle. Many studies have shown that EVs that drive proteins and nucleic acids that are ready to support or suppress tumorigenesis are involved in the growth microenvironment. In addition, it has recently been shown that EV may be involved in oral disorders. Contrast of relative size, proteome marking, and exosome marker intelligibility was observed between the parent and metastatic cells of the OSCC. In addition, OSCC parent cells release ectospores with a single genetic marker that is ready to affect the entire cancer microenvironment. Assessment of exosome markers from OSCC patients can maintain analysis, estimation, and assessment of the patient's response to treatment and distinguish potential growth recurrences. Gradually, there is little research among executives on the role of salivary EV in OSCC. External spores, which are determined by saliva growth, have distinct morphological and elementary particle components, as opposed to solid saliva testing, and can detect changes in illness or threat in high risk patients from the beginning. In the correlation of salivary wide proteomics tests in healthy and OSCC patients, subjective and quantitative factors of salivary EV may support the detection of OSCC and provide data related to visualization of patients with malignant growth. Shown. The salivary EV proteome reveals the presence of proteins involved in disease-causing reactions, metal transport, cell development and proliferation, grouping OSCC patients, and acquiring and providing prognostic data with a high level of accuracy. Enables the ability (Brito JA, et al., 2014).

Discussion

Techniques for Identifying Oral Disease Biomarkers

Biomarkers are detected by various elementary particle methods. B. DNA has high throughput sequencing, polymerase chain response, high quality articulation clusters, limited partial length polymorphisms, ribonucleic acid-protein immunoprecipitation quality chips, and safe precipitation by cross linking, liquid chromatography, and atoms. Shows attractive reverberation, mass spectrometry, protein testing and immunohistochemistry. Focusing on the recognizable evidence of competitors' biomarkers, it truly normalizes review configurations, test panels, and information reviews to provide accurate, substantive, and reliable results for recently awarded biomarkers. Chaietal. We have discovered a potential serum biomarker for lymph node metastasis in oral disease. In their review, serum proteins were evaluated using a proteomics measurement approach. Their results identified gelsolin, fibronectin, angiotensinogen, and haptoglobin as four new biomarkers. Gelsolin was recognized as the newest biomarker in the OSCC test with a brand score of 89% for lymph node energy. In any case, due to the limited sample size mentioned above focused on long longitudinal reviews, these clever biomarkers are expected to be approved for clinical utility. Saliva biomarkers represent a very promising and harmless method for coping with the detection of oral malignancies, and saliva biomarkers provide useful and painless techniques when considering disease cycles and useful responses. Expanded to the given test suite. Over the last two decades, a remarkable number of review papers have been circulated that report unstimulated salivary components and suggest that these components play a possible role in the field of oral biomarkers of malignant growth. In any case, the challenges of saliva biomarker research have highlighted the need to normalize the assortment of saliva tests, evolve sample handling and storage, and reduce widespread variability in harmful and non-cancerous people (Bushati N et al., 2007).

Zeroed in on salivary biomarkers in Serbian OSCC patients in 2011 and uncovered that three salivary proteomics biomarkers and four salivary mRNA biomarkers are essentially connected with late OSCC. Proteomics biomarkers in spit, for example, Interleukin 1b (IL-1B), Interleukin 8 (IL-8), M2BP, and mRNA markers, for example, IL-8, S100P, SAT1, IL-1B are vital levels (Byun JH, (2008)).

Development of Newly Discovered Oral Malignant Growth Indicators

Following the dispersion of fighting oral disease biomarkers, the resulting tests integrate beginning speculation and disclosure examination and support, followed by evaluation of additional data from the revelation. This gives legitimate legitimization, clinical help, and clinical support. Pre-assessment and intelligible testing are performed during the time spent making the up-and-comer's biomarkers. Pre-consistent validness implies the treatment of models attempted using the new scale. The effect subsequent to utilizing the new test can be impacted by (I) time and limit requirements between test arranging and handling. The nature and span of ownership or absence of ownership, and storage time and conditions after model dealing with. Keen legitimization connects with the assessment of explicit pieces of the biomarker that should meet clear models and decides the particularity and acknowledgment of the measure. After additional improvement of the sensible support of the review, biomarkers are tried for cli nical legitimization. The acknowledgment that clinical avocation guarantees that biomarkers separate the number of inhabitants in everyday interest into two distinct gatherings: The people who should encounter the open door and the individuals who are probably not going to encounter the open door. Is connected with. The last cycle for further developing a contender's biomarker is to utilize the Extremely Elevated Levels of Evidence (LOE) to investigate its clinical utility. Biomarkers are then reasonable for use in direct perception studies. This communication includes evaluating the attainability of biomarkers and the level of advantages and misfortunes. It is critical to take note of that regardless of the huge number of biomarkers uncovered in the writing; relatively few disease markers have clinical utility (Cai X et al., 2004).

OSCC Humoral Biomarkers

As referenced over, the humeral components relating to clinical pinnacles are of specific significance given the demonstrated significance of the microenvironment in the beginning and movement of OSCC. VEGF goes about as a model molecule and may connect between unhealthy cells and stromal cells, particularly endothelial cells as displayed. In this section, humeral biomarkers are assigned no matter what their source and system of activity, peregrine or anticrime (Calin GA et al., 2008).

Parathyroid-Related Chemical Protein (PTHrP)

Hoffman and so forth. As of late reported, its receptors overexpressed in OSCC, for example, Endothelin (ET), a new pragmatic biomarker in OSCC. ET contains three little gatherings of peptides, ET-1, ET-2, and ET-3. ET-1 is sent essentially by endothelial cells, ET-2 is communicated by the kidney and stomach related framework, while ET-3 is distinguished basically by the mind. ET applies its properties by restricting cell surface receptors to explicit ET-A (ETAR) and ET-B (ETBR). The two receptors have a place with the g protein- coupled receptor superfamily (Campo-Trapero J et al., 2008).

ETAR ties ET-1 with multiple times more articulated inclination than ET-3, while ETBR ties every one of the three ETs with equivalent inclination. As a general rule, most ET-1 capabilities are utilized in this manner through relationship with ETAR. ET-1, ETAR and ETBR are overexpressed in OSCC, and ET-1 capabilities as a strong part that starts multiplication by means of ETAR and ETBR. HSC-3 cells, a lineage got from human OSCC, showed a huge expansion in ET-1 levels. Commencement of ETAR by ET-1 is a significant reason for malignant growth improvement, development through cell multiplication acknowledgment, perseverance, angiogenesis, and metastasis, and the danger of ETAR might propel sickness therapy. That's what it shows (Kourtis SG et al., 2004).

ET-1 can likewise manage development angiogenesis through VEGF take-up. This is addressed by an expansion in HIF-1 levels because of actuation of ETAR. Aside from adversaries of angiogenesis movement, ET receptor reprobates can likewise keep the arrangement of MMPs from macrophages. In rundown, it is not difficult to feel that restraint of ET receptors, particularly ETAR, might be a helpful choice as an assistant treatment to OSCC. By and large, whether ET rivals offer major clinical advantages to patients with OSCC is a persuading and questionable issue. In a few starter clinical preliminaries in patients with harmful harmless prostatic hyperplasia who were protected from metastatic removal, the ET-1 relentless inhibitor atlascentan was insufficient at fundamental or any endpoint. Identical outcomes were gotten in different examinations with another ET miscreant, zibotentan. Hence, follow-up impacts are normal from OSCC's long an adequate number of clinical leads (Kourtis SG, et al. 2004).

As OSCC Indicators, Endothelins and their Receptors

As of late declared, its receptors overexpressed in OSCC, for example, Endothelin (ET), a new reasonable biomarker in OSCC. ET contains three little gatherings of peptides, ET-1, ET-2, and ET-3. ET-1 is communicated essentially by endothelial cells, ET-2 is sent by the kidney and stomach related framework, while ET-3 is distinguished fundamentally by the mind. ET applies its properties by restricting cell surface receptors to explicit ET-A (ETAR) and ET-B (ETBR). The two receptors have a place with the g protein-coupled receptor superfamily (Tolstunov L et al., 2006).

ETAR ties ET-1 with multiple times more articulated inclination than ET-3, while ETBR ties every one of the three ETs with equivalent inclination. As a general rule, most ET-1 capabilities are utilized in this manner through relationship with ETAR. ET-1, ETAR and ETBR are overexpressed in OSCC, and ET-1 capabilities as a tough part that starts expansion through ETAR and ETBR. HSC-3 cells, a parentage got from human OSCC, showed a critical expansion in ET-1 levels. Commencement of ETAR by ET-1 is a significant reason for malignant growth improvement, development through cell multiplication acknowledgment, perseverance, angiogenesis, and metastasis, and the danger of ETAR might propel sickness therapy. That's what it shows.

ET-1 can likewise control development angiogenesis through VEGF take-up. This is addressed by an expansion in HIF-1 levels because of actuation of ETAR. Aside from adversaries of angiogenesis movement, ET receptor reprobates can likewise keep the arrangement of MMPs from macrophages. In outline, it is not difficult to feel that hindrance of ET receptors, particularly ETAR, might be a helpful choice as an assistant treatment to OSCC. Generally speaking, whether ET rivals offer major clinical advantages to patients with OSCC is a persuading and disputable issue. In a few primer clinical preliminaries in patients with dangerous harmless prostatic hyperplasia who were protected from metastatic removal, the ET-1 vicious inhibitor atlascentan was ineffectual at fundamental or any endpoint. Comparable outcomes were gotten in different examinations with another ET bad guy, zibotentan. Consequently, follow-up impacts are normal from OSCC's long an adequate number of clinical leads (Banoczy J et al., 2001).

Inflammatory Cytokines and Chemokines

Given the specific idea of oral sadness, which is continually being tried by different wounds, including microorganisms, food sources, and engineered substances, its natural molecule parts like cytokines and chemokines are OSCC. A few cytokines and chemokines are really perceived as biomarkers for OSCC. Interleukin (IL)-6 and IL-8 have been involved as promising biomarkers for OSCC. When these cytokines are sent with VEGF, OSCC has been displayed to oppose such that underlies safe effectors. Essentially, the combination of Spit IL-6 in OSCC patients is by and large higher than that of controls, yet the outcomes for IL-8 and development waste element are dubious (Azzam G et al., 2012).

Conclusion

The overview provided an overview of biomarkers, with particular attention to what the elements can apply to OSCC enhancement, exercise, and their harmful potential. As we uncover, in vivo "valuable biomarkers, like RANKL, are especially significant for both the recognition and treatment of this illness. Sadness is for the most part tried by all microorganisms and is related with consuming responses. In response, we have studied RANKL Trigger Specialists from a variety of developmental factors and provocative cytokines that are fundamental to the movement of OSCC cancer, but have not previously been aware of it. CXCL13 can actively regulate RANKL, but in contrast to in vivo upregulation (unpublished results) in the future of our perception and disclosure of remaining related issues, diseased cells and them. The separate microenvironments of are finally reached.

References

1. Azzam G, Smibert P, Lai EC, Liu JL (2012). Drosophila Argonaute 1 and its miRNA biogenesis partners are required for oocyte formation and germline cell division. Dev. Biol. 365(2):384-394.

   [Crossref] [Google Scholar] [PubMed]

2. Bánóczy J, Gintner Z, Dombi C (2001). Tobacco use and oral leukoplakia. J. Dent. Educ. 65(4):322-327.

   [Crossref] [Google Scholar]

3. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zarate R (2006). Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer. 5(1):1-10.

   [Crossref] [Google Scholar] [PubMed]

4. Bansal SK, Leekha S, Puri D. Biochemical changes in OSMF. J. Adv. Med. Dent. Sci. 2013;1(2):101-105.

   [Google Scholar]

5. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M (2011). Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. J. Am. Soc. Hematol. 117(11):3140-146.

   [Crossref] [Google Scholar] [PubMed]

6. Barnes L, Eveson JW, Sidransky D, Reichart P (2005). Pathology and genetics of head and neck tumours. IARC.

   [Google Scholar]

7. Bartel DP (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116(2):281-297.

   [Crossref] [Google Scholar] [PubMed]

8. Bhadage CJ, Umarji HR, Shah K, Välimaa H (2013). Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis. Clin. Oral. Investig. 17(5):1375-1382.

   [Crossref] [Google Scholar] [PubMed]

9. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP (2010). Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approachMicroRNA-based approach for lung cancer classification. Clin. Cancer. Res. 16(2):610-619.

   [Crossref] [Google Scholar] [PubMed]

10. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K (2012). Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene. 31(2):149-160.

    [Crossref] [Google Scholar] [PubMed]

11. Brito JA, Gomes CC, Guimarães AL, Campos K, Gomez RS (2014). Relationship between micro RNA expression levels and histopathological features of dysplasia in oral leukoplakia. J. Oral. Pathol. Med. 43(3):211-216.

    [Crossref] [Google Scholar] [PubMed]

12. Bushati N, Cohen SM (2007). MicroRNA functions. Annu. Rev. Cell. Dev. Biol. 23:175-205.

    [Crossref] [Google Scholar] [PubMed]

13. Byun JH, Park BW, Kim JR, Lee GW, Lee JH (2008). Squamous cell carcinoma of the tongue after bone marrow transplant and graft-versus-host disease: A case report and review of the literature. J. Oral. Maxillofac. Surg. 66(1):144-147.

    [Crossref] [Google Scholar] [PubMed]

14. Cai X, Hagedorn CH, Cullen BR (2004). Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 10(12):1957-1966.

    [Crossref] [Google Scholar] [PubMed]

15. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA. 101(9):2999-3004.

    [Crossref] [Google Scholar] [PubMed]

16. Campo-Trapero J, Cano-Sanchez J, Palacios-Sanchez B, Sanchez-Gutierrez JJ, Gonzalez-Moles MA (2008) Update on molecular pathology in oral cancer and precancer. Anticancer. Res. 28(2B):1197-205.

    [Google Scholar] [PubMed]

17. Kourtis SG, Sotiriadou S, Voliotis S, Challas A (2004). Private practice results of dental implants. Part I: Survival and evaluation of risk factors; Part II: surgical and prosthetic complications. Implant. Dent. 13:373-385.

    [Crossref] [Google Scholar] [PubMed]

18. Kourtis SG, Sotiriadou S, Voliotis S, Challas A (2004). Private practice results of dental implants. Part I: Survival and evaluation of risk factors; Part II: Surgical and prosthetic complications. Implant. Dent. 13:373-385.

    [Crossref] [Google Scholar] [PubMed]

19. Tolstunov L (2006). Dental implant success-failure analysis: A concept of implant vulnerability. Implant. Dent. 15:341-346.

    [Crossref] [Google Scholar] [PubMed]

20. Grunder U (2001). Immediate functional loading of immediate implantsin edentulous arches: Two-year results. Int. J. Periodontics. Restorative. Dent. 21:545-551.

    [Google Scholar] [PubMed]

21. Cavallaro J, Greenstein G, Tarnow DP (2018). Clinical pearls for surgical implant dentistry, part 3. Dent. Today. 29:134-139.

    [Google Scholar]